BOSTON SCIENTIFIC CORP (NYSE:BSX) stands out as a high-growth momentum candidate with a favorable technical setup. The company, a leader in medical device innovation, demonstrates accelerating earnings, expanding profit margins, and consistent revenue growth—qualities that align with momentum investing strategies. At the same time, its stock exhibits strong technical health and a well-defined consolidation pattern, suggesting potential for a breakout.
Growth Momentum Highlights
Earnings & Revenue Growth: BSX posted a 26.2% year-over-year EPS increase (TTM) and a 19.4% revenue growth (TTM). Recent quarterly EPS growth exceeded 20% for three consecutive quarters, with the latest quarter showing a 33.9% surge.
Profit Margin Expansion: Quarterly profit margins improved from 7.9% (Q-3) to 14.5% (most recent quarter), indicating operational efficiency.
Positive Revisions & Surprises: Analysts have raised EPS estimates for the next year by 2%, while the company has beaten earnings expectations in each of the last four quarters by an average of 7.1%.
Technical Rating (10/10): BSX is in a strong uptrend across short and long-term timeframes, outperforming 87% of its healthcare equipment peers.
Setup Quality (8/10): The stock has consolidated between $101.82 and $107.06, with reduced volatility and a recent pocket pivot signal—a bullish accumulation pattern.
Support & Resistance: Key support lies near $93.87 (weekly trendline), while resistance sits between $105.33 and $106.66. A breakout above $106.67 could signal further upside.
This is not investment advice. The observations here are based on current data, but market conditions can change. Always conduct your own research before making investment decisions.